NCT00992342已完成1 期
A Double Blind (3rd Party Open), Randomised, Placebo-Controlled, Dose Escalation Study To Investigate The Safety, Toleration, And Pharmacokinetics Of Multiple Oral Doses Of PF-03893787 In Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- Safety/toleration: Adverse events, vital signs, 12 lead ECG, blood (including creatine kinase) and urine safety tests and physical examination.
研究概览
简要总结
The purpose of this study is to investigate safety and toleration of multiple oral doses as well as the time course of PF-03893787 concentration in the blood following dosing by oral solution.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male subjects and females of non-childbearing potential between the ages of 18 and 55 years.
- •Body Mass Index (BMI) of 17.5 to 30.5 kg/m^2; and a total body weight >50 kg (110 lbs).
排除标准
- •Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
- •A positive urine drug screen.
- •History of regular alcohol consumption exceeding 21 drinks/week for males and 14 drinks/week for females.
研究组 & 干预措施
PF-03893787 5 mg
Experimental
干预措施: PF-03893787 (Drug)
PF-03893787 15 mg
Experimental
干预措施: PF-03893787 (Drug)
PF-03893787 50 mg
Experimental
干预措施: PF-03893787 (Drug)
结局指标
主要结局
Safety/toleration: Adverse events, vital signs, 12 lead ECG, blood (including creatine kinase) and urine safety tests and physical examination.
时间窗: 22 days
次要结局
- Pharmacokinetic parameters: Cmax, Tmax, AUCτ, t½, accumulation ratio,(22 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Japanese Phase 1 Multiple Ascending Dose StudyType 2 Diabetes MellitusNCT01515202Bristol-Myers Squibb40
已完成
1 期
Japanese Phase 1 Multiple Ascending Dose (MAD) StudyDepressionNCT01396252Bristol-Myers Squibb57
已完成
1 期
A Study To Investigate The Safety And Toleration Of A Single Dose Of PF-04418948 In Healthy VolunteersHealthyNCT01002963Pfizer56
已完成
1 期
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E6742 in Systemic Lupus Erythematosus ParticipantsLupus Erythematosus, SystemicNCT05278663Eisai Co., Ltd.26
已完成
1 期
Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses in HealthyHealthy SubjectsOsteoarthritisNCT00380900Wyeth is now a wholly owned subsidiary of Pfizer